Physician profile
Ling Li
NPI 1417135195
$1,031.43
in general payments reported to CMS, 2019-2025
16 companies · $430 in 2025
The $430 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $65.43 · 2024: $536 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,031.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $182.81 | 2023-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $145.98 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Exact Sciences Corporation | $119.90 | 2024-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $85.09 | 2023-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $81.94 | 2024-2025 | Mounjaro, Zepbound |
| Lundbeck LLC | $76.79 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $67.88 | 2024-2025 | Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $55.47 | 2025 | |
| Abbvie INC. | $40.72 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $38.06 | 2025 | Opsumit, Uptravi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.12 | 2024 | Caplyta |
| Vanda Pharmaceuticals INC. | $30.25 | 2025 | Fanapt |
| Shield Therapeutics INC | $21.61 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $20.34 | 2024 | Bevespi Aerosphere |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.06 | 2025 | Xifaxan |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $16.41 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ling Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.